Skip to main content
Clinical Trials/IRCT2017100136491N1
IRCT2017100136491N1RecruitingPhase 2

Evaluation of clinical and histopathological efficacy of carboplatin and gemcitabine as second line neoadjuvant therapy in locally advanced breast cancer patients

Ministry of Research, Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center0 sites50 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 60 years (—)
Sex
Female

Inclusion Criteria

  • Female patients; Diagnosed with locally advanced breast cancer; 18 to 60 years of age. Exclusion criteria: Evidence of metastasis; Inflammatory breast cancer; Abnormal kidney function (Serum creatinine > 1.5 mg/dl); Abnormal liver function (Bilirubin and Serum transaminase > 2xULN); Abnormal Bone marrow function (Abnormal hemoglobin, WBC and platelet count)

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Ministry of Research, Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center

Similar Trials

Studying the effect of addition of... | Clinical Trial